Use of biguanides to improve response to chemotherapy.
Metformin is a commonly utilized antidiabetic agent, which has been associated with improved clinical outcomes in cancer patients. The precise mechanism of action remains unclear, but preclinical evidence suggests that metformin can sensitize tumor cells to the effects to conventional chemotherapeutic agents and ionizing radiation (IR). In this chapter we discuss the general background of an approach to evaluate the effects of metformin on conventional chemotherapeutic agent toxicity in a preclinical model.
Bobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA.
Vlad C
VC
Sandulache
Liangpeng
L
Yang
Heath D
HD
Skinner
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D016923:Cell Death / Q000187:drug effects; D006801:Humans; D008687:Metformin / Q000008:administration & dosage / Q000494:pharmacology*; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D008687:Metformin